Boston Scientific Corp (BSX) · Nov 20, 2026 · New debt

Boston Scientific prices new debt for Penumbra deal

Debt financing — $3.0B USD notes plus €4.25B euro notes

Boston Scientific’s new debt offering funds its planned Penumbra acquisition, improving closing certainty but adding substantial borrowing.

Boston Scientific is a broad medical-device company using the Penumbra acquisition to expand deeper into neurovascular and thrombectomy therapies; the announced transaction carries an enterprise value of about $14.5 billion and is structured roughly 73% in cash and 27% in Boston Scientific shares. This filing turns the acquisition’s funding plan into a priced transaction. Boston Scientific has committed to $3.0 billion of U.S.-dollar notes and €4.25 billion of euro notes, with maturities spanning 2028 to 2046. 〔0〕

USD offeringEuro offering
Principal (Press release)$3.0B€4.25B
Maturities (Press release)2029–20362028–2046
Coupon range (Press release)5.375%–5.875%3.875%–5.125%

The positive is execution certainty, not a new strategic surprise. The proceeds are explicitly intended to fund the cash portion of Penumbra and related costs, and the offerings are expected to close on December 1, 2026. 〔1〕 〔2〕 Because the Penumbra deal and its cash-heavy structure were already public, the main new information is the scale and pricing of the borrowing rather than a change in strategy.

The trade-off is a meaningfully more leveraged transaction. Boston Scientific is not funding the purchase solely with these notes: the filing also points to short-term borrowings, credit-facility debt and cash on hand. If the acquisition fails, most of the notes carry a 101% special mandatory redemption feature, which limits stranded-debt risk but would still leave the company managing a costly financing process. 〔3〕

Bottom line: This is a financing milestone that makes the already-announced Penumbra acquisition more executable, but it does so by adding a large, relatively expensive debt burden. The business story advances modestly; it is not rewritten by the filing yet.,

What to watch next

Offerings close December 1, 2026

Original filing on SEC EDGAR

More Boston Scientific Corp news

Boston Scientific prices new debt for Penumbra deal | BSX Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.